PRECISE CURATE.AI trial: Dr Dean Ho and Dr Raghav Sundar on pilot study exploring guided dosing with XELOX, XELIRI and single agent capecitabine to treat solid tumours
The Phase I and II single-arm pilot study with multiple cohorts of patient populations harnesses AI for personalised guidance of an individual’s dose modulations based only on his/her data. It aims to re-look at the way oncology clinical trials are designed.
Liver cancer trial: Dr Toh Han Chong on ongoing study using Atezolizumab plus Bevacizumab to lower recurrence risk in patients with hepatocellular carcinoma
He leads a Phase III, randomised, open-label study of Atezolizumab plus Bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation.
Breast cancer trial: Dr Yap Yoon Sim on why ongoing clinical trial is significant for patients with PIK3CA-mutant, hormone receptor-positive, Her2-negative, locally advanced or metastatic breast cancer
The phase III, randomised, double-blind, placebo-controlled study evaluates the efficacy and safety of GDC-0077 plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients who meet the specific trial criteria.